ALT Test: What It Actually Measures and What Your Results Mean as a Woman

What ALT Actually Is and Why It Lives in the Liver

ALT stands for alanine aminotransferase. It is an enzyme that catalyzes the transfer of an amino group from alanine to alpha-ketoglutarate, producing pyruvate as part of normal cellular energy metabolism. The liver is by far the richest source of ALT in your body, which is exactly what makes it such a useful marker. When liver cells are healthy and intact, ALT stays inside them. When those cells are damaged or dying, the enzyme leaks out into the blood, where a routine blood draw can detect it.

Why ALT Is More Liver-Specific Than AST

ALT is often ordered alongside AST (aspartate aminotransferase), but the two tell different stories. AST is found in the liver, heart muscle, skeletal muscle, and red blood cells. ALT is concentrated almost exclusively in hepatocytes. So a rise in ALT that is disproportionately higher than AST points squarely at the liver rather than at cardiac or muscle injury. The ratio of AST to ALT, called the De Ritis ratio, is used clinically to distinguish alcoholic liver disease (ratio greater than 2:1) from viral or metabolic liver disease (ratio typically <1).

What the Test Cannot Tell You on Its Own

ALT tells you that liver cells are being damaged. It does not tell you why. A single elevated number prompts a diagnostic investigation, not a diagnosis. Your clinician will pair ALT with AST, alkaline phosphatase, GGT, bilirubin, albumin, a complete blood count, and often imaging before reaching a conclusion.

Normal ALT Ranges for Women: Why the Standard Cut-Off Is Probably Too High

Most hospital labs report a normal range of roughly 7-56 U/L for adults, without separating by sex. That single range is now considered outdated by liver disease researchers. A landmark analysis published in the Annals of Internal Medicine found that the upper limit of normal for ALT should be approximately 19 U/L for women and 30 U/L for men when derived from a metabolically healthy reference population. Using a unisex cut-off means liver disease in women is routinely missed until it is more advanced.

Sex-Specific Thresholds and What They Mean for You

Women generally have lower ALT activity than men for two reasons. First, women carry less skeletal muscle mass, and muscle contributes a small background amount of circulating ALT. Second, estrogen appears to have a hepatoprotective effect that keeps baseline enzyme levels lower during reproductive years. Studies using the NHANES III dataset confirmed that women aged 20-49 had consistently lower ALT than age-matched men, with medians near 15-17 U/L.

If your result comes back at 38 U/L and the lab flags it as "normal," ask your clinician to interpret it against the sex-specific threshold. That number sits above the 19 U/L upper limit of normal for healthy women and warrants at least a repeat fasting test.

How to Read Your Own Lab Report

Your report will list the result, the reference range your lab uses, and an H (high) or L (low) flag. Because reference ranges vary by laboratory method and reagent manufacturer, the absolute number matters less than how it sits relative to the sex-adjusted upper limit of normal. A result of 22 U/L might fall inside one lab's unisex range but above the female-specific threshold. Bring the raw number to your appointment, not just the flag.

How the Menstrual Cycle and Reproductive Hormones Affect ALT

Your hormonal status does not stay neutral while ALT floats in your bloodstream. Estrogen and progesterone both influence liver enzyme activity, meaning the phase of your cycle and your life stage can shift your result by several units.

During Reproductive Years

Estrogen suppresses hepatic triglyceride synthesis and exerts mild anti-inflammatory effects in the liver. Research published in Hepatology showed that premenopausal women had significantly lower rates of metabolic-associated steatotic liver disease (MASLD), partly attributable to estrogen's protective effect on hepatic fat accumulation. Practically, this means your ALT is likely to run at the lower end of the normal range during the estrogen-dominant follicular phase of your cycle.

Oral contraceptive pills (OCPs) can raise ALT slightly in some women, an effect linked to the estrogenic component altering bile composition and hepatic protein synthesis. If you started a new OCP and your ALT ticked up, that association is worth reporting to your clinician.

Perimenopause and Postmenopause

Estrogen withdrawal changes the liver's metabolic environment. As estradiol falls during perimenopause, hepatic fat deposition increases and ALT tends to rise. A cross-sectional study in Menopause found that postmenopausal women had significantly higher rates of MASLD and elevated transaminases compared with premenopausal women of similar BMI and age. Your ALT might cross the female-specific upper limit of normal for the first time in your 50s, not because your lifestyle changed dramatically, but because the hormonal protection you had for decades is no longer present.

If you are on menopausal hormone therapy (MHT), oral estrogen undergoes first-pass liver metabolism and can modestly raise ALT in a small number of women. Transdermal estradiol largely bypasses hepatic first-pass metabolism, making it the preferred route if your baseline ALT is already elevated.

ALT and PCOS: A Connection Most Women Are Not Told About

Polycystic ovary syndrome affects 8-13% of women of reproductive age, and its metabolic features make the liver a direct target. Insulin resistance, a core feature of PCOS, promotes hepatic de novo lipogenesis, the liver's conversion of excess glucose into fat. A systematic review in Fertility and Sterility found that women with PCOS had a significantly higher prevalence of MASLD compared with controls, with elevated ALT present in approximately 25-30% of PCOS cohorts studied.

Here is a practical framework for thinking about ALT in PCOS across life stages:

| Life Stage | Primary Driver of Elevated ALT in PCOS | What to Ask About | |---|---|---| | Teens and early 20s | Insulin resistance, visceral fat | Fasting insulin, HbA1c, liver ultrasound | | Reproductive years | MASLD plus OCP or metformin use | Repeat ALT after 3 months of metformin; check baseline before starting OCPs | | Trying to conceive | Inositol supplementation may lower ALT | Monitor ALT if starting letrozole (mild transient elevation possible) | | Perimenopause | Compounded insulin resistance plus estrogen loss | Annual ALT; consider transdermal MHT if liver enzymes are borderline |

Metformin, frequently prescribed for PCOS, can paradoxically lower ALT over time by improving insulin sensitivity and reducing hepatic fat. A 2009 trial published in Hepatology showed metformin reduced ALT by a mean of 12 U/L in women with MASLD and insulin resistance over 48 weeks. If you have PCOS and are already taking metformin, a falling ALT is a sign the medication is doing more than managing blood sugar.

ALT During Pregnancy: When "Normal" Changes Completely

Pregnancy rewires the liver's physiology. Blood volume expands by up to 50%, serum albumin falls, and hepatic blood flow is partially redirected. These changes mean that standard reference ranges from non-pregnant populations do not apply.

First and Second Trimesters

ALT typically falls in the first and second trimesters due to hemodilution. A value of 10-12 U/L that looks low is usually normal in mid-pregnancy. ACOG notes that alkaline phosphatase rises substantially in pregnancy (due to placental production), but ALT and AST should remain within or below the non-pregnant reference range through the first two trimesters.

Third Trimester and Red Flags

A rising ALT in the third trimester demands urgent evaluation. Three serious conditions cause it:

1. Intrahepatic cholestasis of pregnancy (ICP): ALT rises alongside bile acids; associated with preterm birth and stillbirth risk. Total bile acids above 40 micromol/L define severe ICP. Treatment is ursodeoxycholic acid 500 mg twice daily.
2. HELLP syndrome: Part of the preeclampsia spectrum. ALT and AST rise sharply, platelets fall, and hemolysis markers are present. This is a medical emergency.
3. Acute fatty liver of pregnancy (AFLP): Rare but life-threatening. ALT may be only moderately elevated (100-500 U/L) relative to the severity of illness.

A 2021 ACOG Practice Bulletin on liver disease in pregnancy states that any ALT above the upper limit of the trimester-specific reference range warrants repeat testing within 48-72 hours and consideration of specialist referral.

Postpartum

ALT can transiently rise in the first two weeks postpartum as the liver readjusts to non-pregnant physiology. Postpartum thyroiditis, which affects up to 10% of women in the first year after delivery, can produce mild ALT elevation alongside thyroid dysfunction. If your postpartum labs show an elevated ALT, ask for a TSH alongside the repeat liver panel.

What Causes a High ALT: The Main Conditions to Know

The most common causes of a raised ALT in women, ranked by frequency in primary care settings, are:

• MASLD (metabolic-associated steatotic liver disease): The most common liver disease globally. Formerly called NAFLD. Closely tied to insulin resistance, obesity, and PCOS.
• Alcohol-related liver disease: Women develop alcoholic liver injury at lower intake levels than men and progress to cirrhosis faster due to differences in gastric alcohol dehydrogenase activity.
• Drug-induced liver injury (DILI): Statins, methotrexate, amoxicillin-clavulanate, nitrofurantoin, and herbal supplements are frequent culprits. Women may be at higher risk of DILI from some agents. The FDA's Drug-Induced Liver Injury Network (DILIN) data shows women account for approximately 59% of DILI cases reported.
• Thyroid disease: Both hypothyroidism and hyperthyroidism can raise ALT. Hypothyroid-related myopathy releases muscle-derived enzymes including a small ALT fraction. Always check TSH when ALT is unexpectedly elevated without an obvious cause.
• Viral hepatitis: Hepatitis B and C can produce ALT elevations ranging from mild (2-3x upper limit of normal) to dramatic (10-50x in acute infection).
• Autoimmune hepatitis: More common in women than men, with a female-to-male ratio of roughly 3.6:1. Presents with elevated ALT and positive ANA or anti-smooth muscle antibody.

A Note on Supplements and Herbal Products

Green tea extract, high-dose vitamin A, kava, black cohosh (sometimes used for menopause symptoms), and protein powders containing undisclosed ingredients have all been documented as causes of hepatotoxicity. If you take any supplement and your ALT is elevated, tell your clinician every product you use, including ones you consider "natural." The NIH LiverTox database documents over 1,000 herbal and dietary supplements associated with liver injury.

What Causes a Low ALT and Does It Matter?

A low ALT is rarely discussed, but it is not meaningless. Values consistently below 7 U/L can occur with:

• Vitamin B6 (pyridoxine) deficiency: ALT requires B6 as a cofactor. Severe deficiency blunts ALT production, which can paradoxically mask liver disease by keeping the enzyme falsely low. Women on OCPs have lower B6 levels on average.
• Chronic kidney disease: Reduced ALT production has been reported in advanced CKD, creating a false reassurance in a population already at higher cardiovascular risk.
• Cirrhosis end-stage: When the liver has lost enough functional mass, it can no longer produce adequate ALT, so a "normal" or low result in someone with known liver disease may signal loss of synthetic capacity rather than recovery.

A low ALT does not generally prompt treatment on its own, but it is worth noting in the clinical context, particularly if you are on an OCP, have poor nutritional intake, or have a history of chronic disease.

How to Lower an Elevated ALT: Evidence-Based Approaches for Women

If your ALT is high, the approach depends on the cause. Here are the strategies with the best evidence for the conditions most common in women.

Lifestyle Modifications for MASLD

Weight loss of 5-10% of body weight reduces hepatic fat and lowers ALT reliably. The NASH Clinical Research Network Fatty Liver Treatment Trial showed that a 7% weight loss reduced ALT by a mean of 20 U/L and improved liver histology in participants with MASLD. A Mediterranean-style dietary pattern, low in added sugar and refined carbohydrates, is the dietary approach with the strongest evidence for reducing liver fat.

Exercise lowers hepatic fat independent of weight loss. A 2012 meta-analysis in the Journal of Hepatology found that aerobic exercise reduced ALT by a mean of 10 U/L even without significant weight change. The dose was roughly 150 minutes per week of moderate-intensity activity.

GLP-1 Receptor Agonists

Semaglutide and other GLP-1 receptor agonists reduce hepatic fat accumulation by lowering caloric intake, improving insulin sensitivity, and possibly through direct hepatic effects. The NASH trial of semaglutide 2.4 mg weekly published in the New England Journal of Medicine showed significant reductions in liver fat and ALT compared with placebo over 72 weeks. GLP-1 agonists are being explored as a treatment specifically for MASLD, a condition disproportionately relevant to women with PCOS and those in postmenopause.

Removing the Offending Agent

If DILI is suspected, stopping the causative drug is the first intervention. ALT typically falls within 4-8 weeks of discontinuation if drug injury is the sole cause. Your clinician may re-challenge cautiously or switch to an alternative agent.

Managing Underlying Thyroid or Hormonal Conditions

Treating hypothyroidism with levothyroxine can normalize ALT within 3-6 months. In women with PCOS, combined approaches targeting insulin resistance, including metformin, lifestyle change, or GLP-1 therapy, tend to bring ALT down alongside other metabolic markers.

Who Should Be Monitored More Closely

Some women warrant more frequent ALT monitoring than the general population:

• Women with PCOS, particularly those with BMI >27 or insulin resistance
• Women on long-term methotrexate (for rheumatoid arthritis, psoriasis, or ectopic pregnancy treatment)
• Women on tamoxifen for breast cancer prevention or treatment
• Women taking statins with a pre-existing liver condition
• Women in perimenopause or postmenopause with new-onset metabolic syndrome
• Women with a family history of autoimmune hepatitis or hemochromatosis
• Pregnant women with any third-trimester symptoms (right upper quadrant pain, nausea, jaundice)

AASLD guidelines recommend baseline ALT before starting potentially hepatotoxic medications and repeat testing at 4-12 weeks after initiation.

Evidence Gaps: What We Don't Know Yet About ALT in Women

Women have been systematically under-enrolled in liver disease trials. Most reference range studies that set the upper limit of normal were conducted in populations with more men than women, and few have stratified results by menopausal status or hormonal contraceptive use. A 2023 editorial in Hepatology called for sex-disaggregated reporting in all MASLD trials, noting that treatment response data is currently inadequate to say with confidence whether women respond differently to antifibrotic agents than men.

What this means for you: if your ALT is mildly elevated and your clinician is uncertain of the cause, you are not in a minority. The data to guide that conversation is genuinely thinner than it should be. Asking for a referral to a hepatologist or a clinician experienced in women's metabolic health is a reasonable step, not an overreaction.

Pregnancy and Lactation: What You Need to Know About This Lab Test

ALT itself is only a test, not a drug, so there is no pregnancy category or lactation transfer to discuss. The relevant safety questions center on what conditions a high ALT might reveal and how those conditions are managed during pregnancy and breastfeeding.

During pregnancy, any ALT above the trimester-adjusted reference range should be evaluated for ICP, preeclampsia-related liver disease, and AFLP before attributing it to benign causes. Ursodeoxycholic acid for ICP is the only pharmacologic treatment with sufficient safety data to be recommended during pregnancy. ACOG Practice Bulletin 232 on ICP supports ursodeoxycholic acid at 10-15 mg/kg/day as first-line pharmacotherapy.

During breastfeeding, the priority is ensuring that any hepatotoxic medication you were taking before or during pregnancy is reviewed for lactation safety before you restart it. Statins, for example, are contraindicated in breastfeeding. Metformin is considered compatible with breastfeeding by the American Academy of Pediatrics but discuss the specifics with your prescribing clinician. A baseline ALT at your 6-week postpartum visit is worth requesting if your pregnancy involved any liver-related complication.